Physician profile
Michael A Mistretta
NPI 1003832817
$12,666.34
in general payments reported to CMS, 2019-2025
39 companies · $2,739 in 2025
The $2,739 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $477 · 2021: $1,630 · 2022: $1,677 · 2023: $2,192 · 2024: $2,397 · 2025: $2,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,173 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,173.07 |
| Education | $155.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,186.62 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $2,105.68 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Grifols USA, LLC | $979.66 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $902.42 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genentech USA, INC. | $770.15 | 2019-2025 | Xolair |
| Amgen INC. | $587.94 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $521.39 | 2022-2025 | Dupixent |
| Genzyme Corporation | $480.19 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $412.22 | 2020-2025 | Acthar |
| Insmed, INC. | $385.51 | 2019-2025 | Arikayce |
| Ani Pharmaceuticals, INC. | $379.39 | 2023-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $369.72 | 2019-2024 | Hillrom - Monarch Airway Clearance System |
| Novartis Pharmaceuticals Corporation | $330.55 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $321.98 | 2019-2025 | Winrevair, Capvaxive, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $269.81 | 2023-2025 | Glassia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $258.33 | 2022-2025 | Tyvaso, Tyvaso, Remodulin |
| Mylan Specialty L.P. | $248.02 | 2020-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $220.48 | 2022-2024 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $147.44 | 2021-2025 | |
| Ethicon US, LLC | $117.12 | 2022 | |
| Mallinckrodt Enterprises LLC | $88.44 | 2019 | |
| Pfizer INC. | $84.37 | 2023-2025 | |
| Vifor Pharma, INC. | $73.36 | 2024 | Zemaira |
| Inogen, INC. | $64.28 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Paratek Pharmaceuticals, INC. | $40.75 | 2021 | |
| Pulmonx Corporation | $35.00 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Philips North America LLC | $30.50 | 2020-2022 | |
| Electromed, INC. | $26.57 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $26.50 | 2021 | |
| Atricure, INC. | $25.58 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Teva Pharmaceuticals USA, INC. | $25.45 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $24.38 | 2025 | Alvesco |
| Viatris Specialty LLC | $23.88 | 2025 | Yupelri |
| Nabriva Therapeutics, Plc | $20.33 | 2021 | |
| Biogen, INC. | $19.99 | 2025 | Spinraza |
| Sunovion Pharmaceuticals INC. | $19.67 | 2019 | |
| Pharming Healthcare, INC. | $15.42 | 2023 | Ruconest |
| Gilead Sciences, INC. | $15.01 | 2019 | |
| Sandoz INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mistretta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.